knowledge -WSS

knowledge

author：hotspot 2025-10-01 23:31:36 - browse：1

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： #NeedHerScience: shining a light on gender disparities in medicine

focus

WSS

Let's speed up science by embracing open access publishing

The strategy behind pharma's lawsuits over drug pricing reform

Shifting the focus from loneliness to social health

The strategy behind pharma's lawsuits over drug pricing reform

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Shifting the focus from loneliness to social health

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Cancer drug shortages should be causing more outrage

3 hurdles to bringing medical devices to the U.S. market

After affirmative action ruling, medical educators look to 'holistic review'

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Anesthesiologist group: stop taking Ozempic before surgery

New guidelines on severe brain injury complicate already difficult decisions

Guidelines to prevent youth baseball injuries need more muscle

Do masks work? RCTs can't tell us

hotspot

What would happen to your eyes if you looked at the solar eclipse?

Ionis drug prevents swelling attacks due to hereditary angioedema

Death of patient in Alzheimer’s trial raises question of possible risks

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

FDA's Pazdur wants cancer trials to range beyond China alone

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

focus

focus

hotspot

entertainment